ReviewCurrent opinion in HIV and AIDS2014
Factors contributing to risk for cancer among HIV-infected individuals, and evidence that earlier combination antiretroviral therapy will alter this risk.
Review in Current opinion in HIV and AIDS, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 4 syntheses or guidelines pooled it, 79 citations in OpenAlex.
- Genetic variation near CXCL12 is associated with susceptibility to HIV-related non-Hodgkin lymphoma.Haematologica · 2021Pooled it
- Risk of Colorectal Cancer and Associated Mortality in HIV: A Systematic Review and Meta-Analysis.Journal of acquired immune deficiency syndromes (1999) · 2017Pooled it
- Cancer risk factors among people living with HIV/AIDS in China: a systematic review and meta-analysis.Scientific reports · 2017Pooled it
- Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: a meta-analysis.AIDS (London, England) · 2016Pooled it
- Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV Infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016Trial
- Article
- Review
- NADCdb: A Joint Transcriptomic Database for Non-AIDS-Defining Cancer Research in HIV-Positive Individuals.International journal of molecular sciences · 2026Article
- Article
- Mortality and Non-Fatal Clinical Outcomes After the Most Common Cancers in People with HIV: A Multicohort Collaboration.Cancers · 2025Article
- Cancer in children living with HIV: challenges and perspectives in the antiretroviral therapy era.World journal of pediatrics : WJP · 2025Article
- HIV-1 Viremia and Cancer Risk in 2.8 Million People: The South African HIV Cancer Match Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Cancer incidence in people with HIV in Italy: Comparison of the ICONA COHORT with general population data.International journal of cancer · 2025Article
- Circulating Biomarker Panorama in HIV-Associated Lymphoma: A Bridge from Early Risk Warning to Prognostic Stratification.Biomolecules · 2025Review
- Primary central nervous system lymphomas at a tertiary academic hospital in Johannesburg.Journal of the colleges of medicine of South Africa · 2025Article
- Cancer in People with HIV.Infectious disease clinics of North America · 2024Review
- "I Thought Cancer was a Tobacco Issue": Perspectives of Veterans with and without HIV on Cancer and Other Health Risks Associated with Alcohol and Tobacco/Nicotine Use.AIDS and behavior · 2024Article
- Review
- Measures of Longitudinal Immune Dysfunction and Risk of AIDS and Non-AIDS Defining Malignancies in Antiretroviral-Treated People With Human Immunodeficiency Virus.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Long noncoding RNAs (lncRNAs) in HIV-mediated carcinogenesis: Role in cell homeostasis, cell survival processes and drug resistance.Non-coding RNA research · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
purpose of reviewTo critically appraise recent published literature about factors associated with cancer risk likely to be influenced by combination antiretroviral therapy (cART) in HIV-infected individuals, and the potential of earlier cART initiation to reduce this risk. RECENT
findingsFactors leading to increased risk of non-AIDS-defining malignancies (NADMs) in particular remain poorly understood. Immunodeficiency appears to be key, whereas evidence is emerging that a direct pro-oncogenic effect of HIV, activated inflammatory and coagulation pathways, and cART toxicity may also contribute. By reducing HIV replication, improving immune function, and limiting chronic inflammation, cART initiation at higher CD4 cell counts may, therefore, reduce NADM risk. However, cART only partly normalizes enhanced inflammation and coagulation seen during HIV infection and conflicting laboratory and epidemiological data have been reported as to whether (and how) cART affects NADM risk. Furthermore, secondary analyses of randomized controlled trials comparing early versus delayed cART initiation were inconclusive. SUMMARY: Continuous epidemiological surveillance is warranted to monitor trends in cancer incidence among HIV-infected individuals and to better understand the impact of earlier cART on NADM risk. The role of adjuvant anti-inflammatory or antithrombotic therapies to reduce cancer risk deserves further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.